The Oligonucleotide Therapeutics Society (OTS) is an open, nonprofit forum to foster research and development of oligonucleotide therapeutics.
The Founders’ vision was to bring together the expertise from different angles of oligonucleotide research to create synergies and to bring the field of oligonucleotides to its full therapeutic potential. A new era of oligonucleotide drugs was envisioned that would change the landscape of therapeutic modalities.
Oligonucleotide therapeutics are now being used to successfully treat diseases and have the potential for widespread application. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. Incredibly, oligonucleotide therapeutics have also been used to create an individualized treatment for one single person with a rare, fatal disease.
Upload your resume
Rodendijk 60 X
2980 Zoersel, Belgium
+32 (0) 3 296 01 51
General Inquiry: email@example.com
Job Opportunities: HR@2bridge.be
Service & Solution: BD@2bridge.be
2 Bridge NV is a recognized service provider for the KMO portefeuille (SME portfolio) for providing strategic advice(DV.A222333) and training (DV.O214140).
2 Bridge obtained the Crédit Impots Recherche (CIR) Accreditation for the years 2021, 2022, and 2023, an initiative of the French government to provide tax credit for R&D services.
© 2023 2 Bridge. website by EHBOntwerp